Work

Integrative molecular subtypes of acute myeloid leukemia

Year: 2023

Type: article

Abstract: AML is a heterogenous disease characterized by distinct clinical courses and prognoses based on genomic, epigenomic and transcriptomic profiles [ 1 , 2 ]. Therefore, molecular classification and risk stratification are essential for clinical decision. Although cytogenetics is one of the most powerful prognostic indicators in AML, more than 50% of AML patients have normal karyotypes. In the past decade, advances in sequencing technology enabled incorporation of somatic mutations into molecular classification and risk stratification in AML [ 3 , 4 ]. Additionally, recent studies demonstrated that gene expression profiles in leukemia stem cells and maturation state of AML cells also carry independent prognostic significance [ 5 , 6 ]. Furthermore, DNA methylation patterns may provide additional prognostic values in AML [ 7 , 8 ]. Although multi-omics profiles have been used to define AML molecular subtypes with distinct prognoses, they have not been systematically integrated to define integrative subtypes (iSubtypes) of AML. Therefore, there is a great clinical interest to identify AML iSubtypes and the patterns across multi-omics profiles that could be used for prognosis and targeted therapy.

Source: Blood Cancer Journal

DOI: 10.1038/s41408-023-00836-4